ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.
Sponsor: Alberta Health services
Terminated
Enrolment was suspended on 22may2020, after Mehra et al (Lancet 2020) then stopped due to lack of Covid19 cases.
Listed as NCT04329611, this PHASE3 trial focuses on COVID-19 and remains terminated or withdrawn. Sponsored by Alberta Health services, it has been updated 10 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Nov 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Nov 2022 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 5 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Aug 2020 — Nov 2020 [monthly]
Terminated PHASE3
Status: Suspended → Terminated
-
Jul 2020 — Aug 2020 [monthly]
Suspended PHASE3
Status: Recruiting → Suspended
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE3
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE3
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alberta Health services
- Alberta Innovates Health Solutions
- Calgary Health Trust
- Dr. Michael Hill
- Government of Alberta
- University of Alberta
- University of Calgary
For direct contact, visit the study record on ClinicalTrials.gov .